Skip to content

Drug interactions

Cabozantinib + Lorlatinib

Severity: Moderate

Cabozantinib and Lorlatinib: moderate interaction.

Last updated

For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.

Summary

Lorlatinib induces CYP3A4, which can reduce cabozantinib plasma concentrations and potentially lessen antitumor efficacy. The effect is predicted from the inducing activity of lorlatinib.

What this interaction means in plain words

Cabozantinib and Lorlatinib can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken.

Cabozantinib belongs to Oncology; Lorlatinib belongs to Oncology.

Evidence level: Moderate

Why it happens

Lorlatinib induces CYP3A4, accelerating the metabolism of cabozantinib.

What to do

Monitor for reduced response to cabozantinib. Per cabozantinib labeling for strong CYP3A4 inducers, a dose increase may be considered, with dose reduction after the inducer is stopped.

What to ask your pharmacist

  • Should I take them at different times of day?
  • Does the dose of either medicine need to change?
  • Is there anything I should avoid, such as alcohol or certain foods, while on both?

Bring a full list of your medicines, including over-the-counter products, supplements and herbal remedies, to every pharmacy visit.

Pro+ members

Unlock the full page

Create an account and start a Pro+ trial to unlock the full management advice for Cabozantinib and Lorlatinib, the additional notes, the evidence detail and the whole-prescription interaction checker.

  • Full clinical management advice
  • Additional notes
  • Evidence detail
  • Interaction checker for a whole prescription

Try Pro+ free for 14 days on the web. No card needed.

Frequently asked questions

Can I take Cabozantinib with Lorlatinib?

MediHelp rates the interaction as moderate. Cabozantinib and Lorlatinib can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken. Lorlatinib induces CYP3A4, which can reduce cabozantinib plasma concentrations and potentially lessen antitumor efficacy. The effect is predicted from the inducing activity of lorlatinib.

How serious is the interaction between Cabozantinib and Lorlatinib?

MediHelp rates it moderate, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Monitor for reduced response to cabozantinib. Per cabozantinib labeling for strong CYP3A4 inducers, a dose increase may be considered, with dose reduction after the inducer is stopped.

What other medicines interact with Lorlatinib?

MediHelp also lists interactions of Lorlatinib with, for example, Amobarbital, Apalutamide, Butabarbital. The full list is on the Lorlatinib page.

Full monographs, dosing and an interaction checker in the MediHelp app

Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.

Browse A–Z · Drug interactions

Get the app Sign in